Posted in M&A / Deals Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B April 1, 2026 BioSpace While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach. M&A / DealsMetabolic & GLP-1Read full story